236 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCVInfected Patients: The Phase 3 Ion-2 Study

2014 ◽  
Vol 146 (5) ◽  
pp. S-904
Author(s):  
Paul Y. Kwo ◽  
K. Rajender Reddy ◽  
Paul J. Pockros ◽  
Adrian M. Di Bisceglie ◽  
Sanjeev Arora ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Genotype 1 ◽  
Phase 3 ◽  
Dose Combination

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

2014 ◽  
Vol 146 (5) ◽  
pp. S-903 ◽  
Author(s):  
Ira M. Jacobson ◽  
Patrick Marcellin ◽  
Alessandra Mangia ◽  
Paul Y. Kwo ◽  
Graham Foster ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Genotype 1 ◽  
Phase 3 ◽  
Treatment Naïve ◽  
Dose Combination

scholarly journals Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

JAMA ◽  
2015 ◽  
Vol 313 (17) ◽  
pp. 1728 ◽  
Author(s):  
Fred Poordad ◽  
William Sievert ◽  
Lindsay Mollison ◽  
Michael Bennett ◽  
Edmund Tse ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Genotype 1 ◽  
Hcv Genotype ◽  
Dose Combination ◽  
Hcv Genotype 1
Sign in / Sign up

Export Citation Format

Share Document